ATE455552T1 - Expression des active human factor ix im brustdrüsengewebe transgener tiere - Google Patents

Expression des active human factor ix im brustdrüsengewebe transgener tiere

Info

Publication number
ATE455552T1
ATE455552T1 AT98906318T AT98906318T ATE455552T1 AT E455552 T1 ATE455552 T1 AT E455552T1 AT 98906318 T AT98906318 T AT 98906318T AT 98906318 T AT98906318 T AT 98906318T AT E455552 T1 ATE455552 T1 AT E455552T1
Authority
AT
Austria
Prior art keywords
factor
transgenic animals
dna
mammary gland
expression
Prior art date
Application number
AT98906318T
Other languages
English (en)
Inventor
John Johnson
William Velander
William Drohan
Henryk Lubon
Original Assignee
American Nat Red Cross
Virginia Tech Intell Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Nat Red Cross, Virginia Tech Intell Prop filed Critical American Nat Red Cross
Application granted granted Critical
Publication of ATE455552T1 publication Critical patent/ATE455552T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98906318T 1997-02-14 1998-02-13 Expression des active human factor ix im brustdrüsengewebe transgener tiere ATE455552T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3714597P 1997-02-14 1997-02-14
PCT/US1998/002638 WO1998035689A1 (en) 1997-02-14 1998-02-13 Expression of active human factor ix in mammary tissue of transgenic animals

Publications (1)

Publication Number Publication Date
ATE455552T1 true ATE455552T1 (de) 2010-02-15

Family

ID=21892688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906318T ATE455552T1 (de) 1997-02-14 1998-02-13 Expression des active human factor ix im brustdrüsengewebe transgener tiere

Country Status (9)

Country Link
US (4) US6344596B1 (de)
EP (1) EP0971724B1 (de)
JP (2) JP2001522230A (de)
AT (1) ATE455552T1 (de)
AU (1) AU735463B2 (de)
CA (1) CA2280700A1 (de)
DE (1) DE69841459D1 (de)
ES (1) ES2340008T3 (de)
WO (1) WO1998035689A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455552T1 (de) * 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
GB9825374D0 (en) * 1998-11-19 1999-01-13 Ppl Therapeutics Scotland Ltd Method
AU2492400A (en) * 1999-01-06 2000-07-24 Atlantic Biopharmaceuticals, Inc. Expression of secreted human alpha-fetoprotein in transgenic animals
DE60044301D1 (de) * 2000-12-22 2010-06-10 Agronomique Inst Nat Rech Positionsunabhängige und gewebespezifische Expression eines Transgens in der Milch eines Transgen-Tieres
MXPA03008209A (es) * 2001-03-12 2004-11-12 Progenetics Llc Produccion de altos niveles del factor viii transgenico con estabilidad disenada, y sus usos terapeuticos.
US20040133930A1 (en) * 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
EP1418810A4 (de) * 2001-08-03 2006-08-02 Us Gov Health & Human Serv Orale behandlung von hämophilie
WO2003054182A2 (en) * 2001-12-21 2003-07-03 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
US20040162414A1 (en) * 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
US7514593B2 (en) * 2003-05-30 2009-04-07 The University Of North Carolina At Chapel Hill Animal model for chronic obstructive pulmonary disease and cystic fibrosis
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
JP2007524693A (ja) 2004-02-20 2007-08-30 ザ バーナム インスティチュート 抗菌性の糖質及びそれを用いた方法
US7663019B2 (en) * 2006-05-24 2010-02-16 North Carolina State University Transgenic snakes and methods of making
EP2423305A1 (de) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modifizierte Gerinnungsfaktor-IX-Polypeptide und deren Verwendung bei der Behandlung
US8124831B2 (en) * 2006-07-06 2012-02-28 Duke University Transgenic mice carrying functional single nucleotide polymorphisms in brain-specific tryptophan hydroxylase
EP2125866B1 (de) * 2007-02-28 2013-05-22 Baxter International Inc. Verfahren zur reinigung von mit sulfatierten und/oder phosphorylierten molekülen angereichtem rekombinantem blutgerinnungsfaktor ix
EP2147096B1 (de) 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modifizierte Faktor-VII-Polypeptide und Verwendungen davon
WO2009118460A1 (fr) * 2008-03-25 2009-10-01 Bioprotein Technologies Sa Lapins transgeniques producteurs de facteur vii humain
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
DK2337849T3 (en) 2008-09-15 2018-10-01 Uniqure Biopharma B V FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF
US9056114B2 (en) 2009-08-28 2015-06-16 Jeffrey P. Erickson Chemical induction of lactation
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
NZ603289A (en) 2010-04-29 2014-07-25 Baxter Int Purification method for divalent cation binding proteins on anion exchange resin
EP2590668A4 (de) * 2010-07-09 2014-04-02 Biogen Idec Hemophilia Inc Faktor-ix-polypeptide und verfahren zu ihrer verwendung
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2012075138A1 (en) * 2010-11-30 2012-06-07 Progenetics Llc Method of producing biologically active vitamin k dependent proteins in transgenic animals
LT2748179T (lt) * 2011-10-14 2022-04-11 Takeda Pharmaceutical Company Limited Baltymų gryninimas anijonų mainų chromatografija
JP6117219B2 (ja) 2011-10-14 2017-04-19 バクスアルタ ゲーエムベーハー 陰イオン交換クロマトグラフィによるタンパク質の精製方法
US9980471B2 (en) * 2012-06-12 2018-05-29 The General Hospital Corporation Miniature swine transgenic for one or more coagulation factors
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
BR112015011462A2 (pt) 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
WO2014140289A1 (en) 2013-03-15 2014-09-18 Baxter International Inc. Purification method for vitamin k dependent proteins by anion exchange chromatography
JP6800863B2 (ja) 2015-02-06 2020-12-16 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 最適化されたヒト凝固第ｖｉｉｉ因子遺伝子発現カセットおよびその使用
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP4054324A1 (de) 2019-11-05 2022-09-14 Versiti Blood Research Institute Foundation, Inc. Mausmodell von fetaler/neonataler allogener thrombozytopenie
US11266129B2 (en) 2019-11-05 2022-03-08 Versiti Blood Research Institute Foundation, Inc. Murine model of fetal/neonatal alloimmune thrombocytopenia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125409B (en) * 1982-08-04 1985-11-13 Nat Res Dev Genetic engineering
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8826446D0 (en) 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
EP0737746A3 (de) 1989-12-01 1996-10-23 Pharming B.V. Herstellung rekombinanter Polypeptide durch Rinderarte und Transgenmethoden
JPH04365487A (ja) * 1990-04-11 1992-12-17 Consortium Elektrochem Ind Gmbh 組換ｄｎａ−構造体、組換ベクター、トランスゲン動物の乳からの蛋白質の取得法、トランスゲン動物の製法及びトランスゲン動物の乳
ATE211177T1 (de) * 1991-01-11 2002-01-15 American Nat Red Cross Expression von aktivem menschlichem protein c im milchdrüsengewebe transgener tiere
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
DE69535604T2 (de) * 1994-02-18 2008-05-21 American National Red Cross Transgenes fibrinogen
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
ATE455552T1 (de) * 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere

Also Published As

Publication number Publication date
EP0971724B1 (de) 2010-01-20
AU6157198A (en) 1998-09-08
US20090221492A1 (en) 2009-09-03
DE69841459D1 (en) 2010-03-11
US7419948B2 (en) 2008-09-02
EP0971724A4 (de) 2003-01-08
JP2010063462A (ja) 2010-03-25
US20060287228A1 (en) 2006-12-21
US20020166130A1 (en) 2002-11-07
JP2001522230A (ja) 2001-11-13
US6344596B1 (en) 2002-02-05
AU735463B2 (en) 2001-07-12
CA2280700A1 (en) 1998-08-20
JP4936568B2 (ja) 2012-05-23
EP0971724A1 (de) 2000-01-19
WO1998035689A1 (en) 1998-08-20
ES2340008T3 (es) 2010-05-27

Similar Documents

Publication Publication Date Title
ATE455552T1 (de) Expression des active human factor ix im brustdrüsengewebe transgener tiere
ATE211177T1 (de) Expression von aktivem menschlichem protein c im milchdrüsengewebe transgener tiere
Pursel et al. Status of research with transgenic farm animals
EP0807170B1 (de) Transgene schweine, die den menschlichen blutgerinnungsfaktor viii exprimieren
BR9506652A (pt) Materiais e métodos para gerenciamento de rejeição hiperaguda em xenotransplante em ser humano
Westphal Transgenic mammals and biotechnology
CN103966245B (zh) 利用基因敲入和核移植技术在转基因动物生产重组人丁酰胆碱酯酶的方法
CN102226202A (zh) 家蚕中部丝腺细胞合成分泌溶菌酶的方法
Bai et al. Generation of a transgenic cashmere goat using the piggyBac transposition system
Hay et al. Use of genome editing techniques to produce transgenic farm animals
Jänne et al. Transgenic bioreactors
MXPA03008210A (es) Produccion de altos niveles del factor ix transgenico sin rescate del gen, y sus usos terapeuticos.
Paleyanda et al. The expression of therapeutic proteins in transgenic animals
Zinovieva et al. Transgenic farm animals: the status of research and prospects
NO20023709L (no) Transgen dyremodell for fedmeuttrykkende FOXC2
RU2491343C1 (ru) Генетические конструкции ltf3, ltf5, ltf7, ltf10, ltf11 для получения рекомбинантного лактоферрина человека (варианты)
US20040117862A1 (en) Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses
Whitelaw et al. Animal bioreactors.
Shaukat REVIEW ON TRANSGENIC TECHNOLOGY IN LIVESTOCK: CURRENT STATUS AND FUTURE HORIZONS
CN103923215A (zh) 使ACC-α基因启动子PⅢ失活的物质及其应用
Huang et al. Expression of biologically active human clotting factor IX (hF IX) in the mammary gland of transgenic mice
Whitelaw PHARMACEUTICAL PROTEINS FROM MILK OF TRANSGENIC ANIMALS
CN106255532A (zh) 用c1抑制剂治疗遗传性血管性水肿
WO2002052019A3 (en) 22437, a human sulfatase and uses therefor
Drohan et al. Progress in transgenic production of human plasma proteins in mammary bioreactors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties